GALAPAGOS GENOMICS WKN: A0EAT9 ISIN: BE0003818359 Kürzel: GLPG Forum: Aktien Thema: Hauptdiskussion

News out

Auch hier neues 52 Wochentief. 🙈

http://ih.advfn.com/stock-market/NASDAQ/galapagos-nv-GLPG/stock-news/85558245/galapagos-announces-new-data-supporting-rapid-symptom-improvement-and-sustained

Cso geht endlich. Nächstes Jahr Komplettexplosion

Gibts was neues ?

Aus den Earning Call vom Februar : ... And in January, we have highlighted a bit some key numbers in terms of our expectations for Jyseleca. We anticipate that we can make this a EUR0.50 billion product in the second half of this decade. We also anticipate that by then this can be a contribution margin of approximately 50%. And we've also highlighted that we think that this is going to be breakeven in 2024 after three years of investments. So that's -- that should give you some direction as to how we think our spend would evolve...  https://www.fool.com/earnings/call-transcripts/2021/02/19/galapagos-nv-glpg-q4-2020-earnings-call-transcript/?source=iedfolrf0000001

📌.🐢

Buy Deutsche Bank. Target 110 Euro

5 Mrd Cash und MK. Da ist das Kursziel aber sehr konservativ. Imo.

Oh, zu spät 😀

Galapagos Raised to Overweight at Barclays; PT 80 euros By Bloomberg Automation (Bloomberg) -- Barclays analyst Rosie Turner raised the recommendation on Galapagos NV to overweight from equal-weight. PT set to 80 euros, implies a 23% increase from last price. Galapagos average PT is 75.15 euros. Targets updated in the last 3 months range from 62 euros to 192.95 euros

https://boerse-social.com/page/newsflow/research-fazits_zu_aixtron_infineon_dermapharm_schaeffler_basf

Barclays hebt Galapagos auf Overweight: Ziel 80 € (69 €)

Dann nehmen wir halt die EU und Japan😃

Die US-Gesundheitsbehörde FDA hatte die Zulassung für Filgotinib in der Indikation Rheumatoide Arthritis (RA) abgelehnt.. Zumindest ein Hauptgrund

Wieso ging die Aktie damals so stark runter?